Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma

Exclusion Criteria

• •1. Known central nervous system disease such as brain or meninges, including central nervous system lymphoma.
• •2. Congestive heart failure, Class III or IV (New York Heart Association, NYHA);
• •3. Other primary malignancies within the last 3 years (except non-melanoma skin cancer, curatively treated localized prostate cancer, carcinoma in situ of the cervix, or squamous epithelial endothelial lesions on PAP smear)
• •4. Previous use of investigational drugs;
• •5. Any active systemic viral, bacterial, or fungal infection requiring antimicrobial therapy within 2 weeks prior to the first dose of study drug;
• •6. Use of immunosuppressive agents, excluding nasal sprays and inhaled corticosteroids or physiological doses of systemic steroids (i.e., no more than 20 mg/day prednisone or its equivalent) within 7 days prior to the first dose of study drug
• •7. Allergic reactions, anaphylactic reactions and adverse drug reactions
• •1. Severe allergic reactions to other monoclonal antibodies;
• •2. Allergy or intolerance to infusion;
• •3. Patients with a history of serious allergy to the investigational drug or its preventive medication;
• •8. Physical examination and laboratory findings
• •1. Patients with congenital or acquired immunodeficiency, such as active hepatitis B virus (HBV DNA ≥ 500 IU/mL), hepatitis C (hepatitis C antibody positive, and HCV-RNA higher than the lower limit of detection of the analytical method) or combined hepatitis B and C co-infection;
• •2. Pregnant or lactating women; patients with fertility are unwilling or unable to take effective contraceptive measures;
• •3. Known history of positive human immunodeficiency virus (HIV) test or known acquired immunodeficiency syndrome (AIDS);
• •9. Any condition that, in the opinion of the investigator, may jeopardize the subject or may render the subject unable to meet or perform the study requirements;
• •10. Other conditions that the investigator considers inappropriate for entry into this study.